Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[Ru(5-FU)(PPh3)2(bipy)]PF6 is a novel ruthenium-based metal complex that incorporates the chemotherapeutic agent 5-fluorouracil (5-FU). This small molecule complex is designed to enhance the cytotoxicity of 5-FU and target cancer stemness, particularly in colorectal cancer (CRC). Its mechanism of action involves the inhibition of the Akt/mTOR signaling pathway, which leads to the suppression of AKT1 gene transcripts and the reduction of downstream proteins such as mTOR, S6, and 4EBP1. Preclinical studies have demonstrated that the complex induces apoptosis and cytoprotective autophagy, inhibits epithelial-mesenchymal transition (EMT), and reduces the formation of colonospheres. In vivo research using mouse xenograft models has shown its efficacy in inhibiting HCT116 cell development and experimental lung metastases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [Ru(5-FU)(PPh3)2(bipy)]PF6.